Market Leadership TearScience leads innovation in the evaluation and treatment of meibomian gland dysfunction with FDA-cleared devices like LipiFlow and advanced imaging tools such as LipiView II and LipiScan, positioning it as a preferred provider for ophthalmic clinics focusing on dry eye treatments.

Recent Acquisition Bausch Health acquired TearScience in March 2023, indicating strong industry confidence and expanding potential sales channels through a major healthcare conglomerate looking to enhance its ophthalmic portfolio.

Growing Market Demand With approximately 86% of the 300 million dry eye sufferers worldwide affected by MGD, there is a significant and expanding patient base, creating substantial opportunities for clinics and practitioners to adopt TearScience’s innovative diagnostic and treatment solutions.

Product Innovation Timeline TearScience’s continuous innovation, including launching LipiScan, LipiFlow Activator II, and new imaging devices since 2017, demonstrates a strong commitment to product development, inviting strategic sales partnerships with ophthalmic practices seeking cutting-edge solutions.

Strategic Positioning As a privately funded company with a revenue between 1 million and 10 million and a focused technology stack, TearScience presents attractive partnership opportunities for healthcare device distributors aiming to expand their ophthalmic product catalog with proven, FDA-approved technologies.